On April 18, President Trump signed an executive order aimed at accelerating research on ibogaine as a treatment for serious mental illnesses, marking a significant federal endorsement of psychedelic medicine for conditions like PTSD and addiction. This has led to a surge in biotech stocks focused on psychedelics, with some companies witnessing substantial gains. While the order fast-tracks federal review for certain psychedelic drugs, it does not broadly legalize them. It signals a pivotal policy shift that could improve the landscape for psychedelic companies, although experts caution that investments remain risky due to their reliance on clinical trial outcomes. Overall, the executive order transforms a struggling biotech niche into a potentially promising market for mental health treatments.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://investingnews.com/executive-order-boosts-psychedelics-biotech/
